Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
The BSGM news archive on Stock Titan covers the corporate evolution of BioSig Technologies, Inc. into Streamex Corp., a Nasdaq-listed company now trading under the symbol STEX. Company press releases and SEC-referenced announcements document the merger between BioSig Technologies and Streamex Exchange Corporation, the subsequent name change to Streamex Corp., and the ticker change from BSGM to STEX on the Nasdaq Capital Market.
Earlier news items in this history describe BioSig’s activities as a medical device technology company focused on the PURE EP™ Platform for electrophysiology procedures. More recent releases highlight the company’s strategic pivot toward real-world asset tokenization and gold-focused financial infrastructure through Streamex. Disclosures discuss Streamex as a gold tokenization and gold treasury business building institutional-grade infrastructure to bring the gold and commodities markets on chain.
Readers can find coverage of key developments such as the closing of the merger with Streamex Exchange Corporation, public offerings of common stock to purchase gold bullion under an investment policy, and a tokenized yield partnership agreement related to precious-metal lease and bond programs. News items also address plans to operate as a regulated participant in tokenized real-world asset markets, including engaging a specialist firm to manage the acquisition of a FINRA and SEC-registered broker-dealer.
For anyone tracking the company’s journey from its BSGM days to its current STEX identity, this news page provides a chronological view of material announcements, strategic partnerships, capital markets activity, and governance changes that define the transition from a medical device issuer to a gold tokenization and RWA-focused enterprise.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced its PURE EP™ System is installed in six medical centers, facilitating over 350 clinical cases managed by 25 electrophysiologists. The company's evaluation installations are increasing, strengthening its commercial framework for 2021. CEO Kenneth L. Londoner will present at the Benzinga Global Small Cap Conference on December 8, 2020, detailing operational highlights and commercialization goals. The PURE EP™ System enhances ECG and intra-cardiac signal analysis, contributing to advancements in electrophysiology practices.
BioSig Technologies announced its PURE EP™ System will be featured in live cases at EPLive 2020 on December 3-4, 2020, showcasing advancements in treating complex cardiac arrhythmias. The event, hosted at the Texas Cardiac Arrhythmia Institute, will involve 21 live and 13 recorded cases, aimed at educating electrophysiologists and cardiologists. Over 350 cases using the PURE EP™ System have been completed, indicating its growing significance in the field. The company expresses gratitude for the support received during this challenging time due to the pandemic.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced a conference call on November 18, 2020, at 4:15 PM ET, hosted by CEO Kenneth L. Londoner. The call will cover highlights from the third quarter of 2020 and discuss corporate initiatives, including ongoing installations of the PURE EP™ System. Currently, this system is installed in six medical centers, with over 350 patient cases completed. BioSig is also enrolling patients in the PURE EP 2.0 Study at Texas Cardiac Arrhythmia Research Foundation and Mayo Clinic Florida. A replay will be available for two weeks after the call.
BioSig Technologies has commenced operations with its PURE EP™ System at Deborah Heart and Lung Center in New Jersey, marking a significant advancement in its clinical trials. This initiative aims to evaluate the effectiveness of the system in capturing intracardiac signals, crucial for electrophysiology procedures. Led by Dr. Raffaele Corbisiero, the trials are particularly timely due to the COVID-19 pandemic's impact on cardiovascular health. BioSig also expands its clinical study sites, now including prestigious institutions like Massachusetts General Hospital and UPenn.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced notable advancements in its PURE EP™ System, demonstrating growing acceptance with new installations at leading medical centers. With a record cash balance of $36.9 million, the Company is well-positioned for future growth. Recent highlights include new installations at Massachusetts General Hospital and the Hospital of the University of Pennsylvania, along with the acceptance of substantial clinical data abstracts. Despite halting its ViralClear subsidiary's COVID-19 trials, BioSig remains optimistic about expanding its business and product pipeline into 2021.
BioSig Technologies, Inc. (Nasdaq: BSGM) and its subsidiary, ViralClear Pharmaceuticals, have halted their Phase 2 trial studying the efficacy of oral merimepodib combined with remdesivir in severely ill COVID-19 patients. The decision follows an unblinding by the Safety Monitoring Committee, which revealed concerning differences in survival rates between treatment and placebo groups among NIAID Grade 3 patients. With no plans to continue developing merimepodib, the company will explore potential partnerships for its licensing or acquisition.
ViralClear Pharmaceuticals (Nasdaq: BSGM) and Sorrento Therapeutics are collaborating to explore synergistic effects of their antiviral agents against COVID-19. Sorrento will test its STI-1400 antibody alongside ViralClear's oral antiviral, merimepodib. The preclinical study aims to evaluate the combined efficacy in a Golden Syrian hamster model. If successful, results may support future human clinical trials with the drug combination. Merimepodib has shown promise in prior clinical studies, indicating potential for treating COVID-19.
BioSig Technologies, Inc. (Nasdaq: BSGM) has announced an increase in the ongoing Phase 2 trial of its drug merimepodib, now enrolling 80 subjects, focusing on hospitalized COVID-19 patients requiring non-invasive ventilation. The company added two Principal Investigators, expanding the trial to ten locations. A US-based CMO will manufacture Phase 3 supplies of merimepodib oral solution. Additionally, a monotherapy trial will commence post the current trial's completion. These steps reflect significant developments in the drug's clinical evaluation and potential market introduction.
BioSig Technologies (Nasdaq: BSGM) announced a Phase 2 clinical trial of merimepodib in combination with remdesivir for hospitalized patients with COVID-19 requiring supplemental oxygen. The randomized, double-blind, placebo-controlled trial aims to evaluate efficacy and safety at 10 sites across the US, led by Dr. Andrew Badley from the Mayo Clinic. A conference call is scheduled for September 22, 2020, to discuss trial details. Merimepodib has shown antiviral activity against SARS-CoV-2 and was previously investigated for chronic hepatitis C and psoriasis.
BioSig Technologies has announced positive results from the PURE EP study, showcasing its advanced signal processing capabilities compared to conventional systems. An independent analysis rated 85.3% of PURE EP signals as equivalent or superior to standard sources. The study involved data from 15 atrial fibrillation ablation procedures and highlighted that 35.5% of reviewers found more components visible in PURE EP data. Results were presented at ESC Congress 2020, further solidifying BioSig's position in the electrophysiology market.